___ , the only V2 receptor antagonist approved for use in the United States, is approved for the short-term treatment of hypervolemic or euvolemic hyponatremia refractory to fluid restriction. There is concern regarding the use of ___ in patients with liver disease based on the observation of elevated liver enzyme levels in patients receiving ___ compared with placebo in the ___ Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) trial